CivaTech Oncology Inc. offers cancer patients radiation therapy treatment options designed to minimize distress and inconvenience, maximize quality of life and improve life expectancy. The Company has developed to use condition an innovative polymer-based low-dose rate (LDR) brachytherapy devices, pioneering a new standard of care in treatment of various stages of cancer.The firm's first product, called the CivaString®, has been cleared by the FDA for use in localized solid tumors or residual disease, and the product began use to treat prostate cancers in 2013. The Companyâs second product, is a bioabsorbable, planar sheet called the CivaSheet®, received FDA clearance in 2014 and is the first commercially available brachytherapy device that has integrated radiation shielding built into the implantable device, making it more safe and allowing broader applications where previously risk of harming healthy tissue was problematic. Both products are customized for the patient and the strengths can be varied according to the prescription. CivaTech Oncologyâs products are significantly more accurate to prescription than traditional metal encapsulated se
